anti-CD19 antibody-drug conjugate IKS03

{
  "id": "MLC-T-ONC-010248",
  "term": "anti-CD19 antibody-drug conjugate IKS03",
  "field": "Oncology and biomedicine",
  "definition": "An antibody-drug conjugate (ADC) composed of a human monoclonal antibody directed against the tumor-associated antigen (TAA) CD19 (cluster of differentiation 19), that is site-specifically conjugated with a tumor-cleavable beta-glucuronide linker to a tumor-cleavable prodrug of pyrrolobenzodiazepine (PBD) dimer, with potential antineoplastic activity. Upon intravenous administration, the monoclonal antibody moiety of anti-CD19 ADC IKS03 targets and binds to CD19 expressed on tumor cells. Upon binding and internalization, both the linker and prodrug are selectively cleaved by lysosomal b-glucuronidase overexpressed in tumor cells. Free PBD is released and forms highly cytotoxic DNA interstrand cross-links, thereby blocking cell division and killing CD19-expressing cancer cells. CD19 antigen is a B-cell specific cell surface antigen overexpressed in B-cell lineage malignancies.",
  "synonyms": [
    "anti-CD19 ADC IKS03",
    "anti-CD19/PBD ADC IKS03"
  ],
  "references": [
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/anti-cd19-antibody-drug-conjugate-iks03/"
}